BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28370436)

  • 1. Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.
    Major A; Pan Z; Kamdar M
    Am J Hematol; 2017 Nov; 92(11):1267-1268. PubMed ID: 28370436
    [No Abstract]   [Full Text] [Related]  

  • 2. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
    Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of ALK negative CD30+ primary cutaneous anaplastic large cell lymphoma in a young adult.
    Sridevi HB; Shanthala PR; Raghuveer CV; Prabhu AK; Akbar JK; Shivaprasad GS; Suresh PK; Navani S
    J Cancer Res Ther; 2015; 11(3):656. PubMed ID: 26458652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [22-year-old man with T-cell-lymphoma and new skin lesions].
    Kampfenkel T; Schroers R; Kreuter A
    Dtsch Med Wochenschr; 2012 Mar; 137(9):429-30. PubMed ID: 22354798
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous involvement in systemic anaplastic large cell lymphoma.
    Kwok C; Salmo E
    J Dtsch Dermatol Ges; 2015 Jul; 13(7):693-5. PubMed ID: 26031654
    [No Abstract]   [Full Text] [Related]  

  • 6. "Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.
    Luo DX; Li W; Ye MT; Yang Y; Tang G; You MJ
    Am J Hematol; 2020 Dec; 95(12):1625-1627. PubMed ID: 32833271
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
    Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH
    Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748
    [No Abstract]   [Full Text] [Related]  

  • 8. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
    Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
    Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
    Isogai R; Fukao M; Kawada A
    J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity.
    Ok CY; Wang SA; Amin HM
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e123-6. PubMed ID: 24685107
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
    Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
    Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
    [No Abstract]   [Full Text] [Related]  

  • 12. [CD30-negative and ALK-positive anaplastic large cell lymphoma: report of a case].
    Li N; Ren D; Lü BB; Xie JL; Zheng XD; Gong LP; Zhou XG
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):269-70. PubMed ID: 21616006
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
    Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
    Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
    Dawn G; Morrison A; Morton R; Bilsland D; Jackson R
    Clin Exp Dermatol; 2003 Nov; 28(6):620-4. PubMed ID: 14616830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL).
    Eisfeld H; Kircher S; Rosenwald A; Anagnostopoulos I; Werner M; Gaßler N; Wolf G; Lehmkuhl L; Teichgräber U; Gühne F; Darr A; Freesmeyer M; Weschenfelder W; Hofmann G; Dalkilic R; Kalff R; Hochhaus A; Schrenk KG
    Ann Hematol; 2021 Apr; 100(4):1107-1109. PubMed ID: 32895754
    [No Abstract]   [Full Text] [Related]  

  • 16. Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long.
    Moskowitz AJ; Lunning MA; Horwitz SM
    Cancer J; 2012; 18(5):445-9. PubMed ID: 23006950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case.
    Biswas A; Devnani B; Agarwal S; Sharma MC; Sharma A
    J Adolesc Young Adult Oncol; 2019 Aug; 8(4):469-476. PubMed ID: 30994389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated cutaneous involvement in a child with nodal anaplastic large cell lymphoma.
    Mendiratta V; Gandhi N; Rana S; Shukla S;
    Indian J Dermatol Venereol Leprol; 2016; 82(1):53-6. PubMed ID: 26728811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases.
    Matsumoto H; Koga H; Honda K; Sadahira Y; Suetugu Y; Mikami M; Nakanishi H; Yata K; Wada H; Sugihara T; Haruma K
    Gastrointest Endosc; 2005 Apr; 61(4):607-9. PubMed ID: 15812421
    [No Abstract]   [Full Text] [Related]  

  • 20. Anaplastic large-cell lymphoma (Ki-1 lymphoma) with expression of IL-5 mRNA and eosinophilic invasion.
    Takimoto Y; Tanaka H; Tanabe O; Kuramoto A; Sasaki N; Nanba K
    Acta Haematol; 1996; 96(4):245-8. PubMed ID: 8922493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.